A clinical trial for a small-diameter defibrillation lead for implantable cardioverter-defibrillators exceeded safety and efficacy expectations, with 98% successfully implanted and 99.5% placed precisely in the desired location. The lead had a low rate of major complications, no fractures, and high efficacy rates for defibrillation and pacing. The lead, OmniaSecure, is an improvement over previous models, with a thicker insulation layer to prevent cracking. While routine testing is recommended to monitor for potential issues, the lead has shown promising results in the trial. Expert caution for vigilance in monitoring for potential long-term durability issues was also advised.
Source link
Defibrillation Lead Exceeds Expectations in Clinical Trial
